Tested vancomycin dosing for serious MRSA using different lab targets
Treatments studied
Part of Infections clinical trials.
This trial compares two ways of dosing vancomycin (an antibiotic) for serious MRSA infections by using different blood test targets. The goal is to see if the newer approach works at least as well as the standard one, while keeping patients safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18+) with a serious MRSA infection confirmed by culture
- Your MRSA culture was taken within the last 4 days
- You’re either not currently taking vancomycin, or you’ve had vancomycin for 4 days or less
- Your MRSA lab result must show vancomycin MIC less than 2 (how easily the bacteria responds)
- You can’t be on intermittent hemodialysis or peritoneal dialysis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests ways to get rid of MRSA bacteria in the body when it is “complicated,” such as having MRSA outside the nose or an ongoing MRSA infection. It may help reduce future MRSA problems or infections by lowering how long the bacteria stay in your body.
This trial compares two antibiotics, vancomycin and daptomycin, to see which works better for treating MRSA bacteria in the blood. Patients are randomly assigned to one of the drugs and will be monitored closely for results and side effects.
This trial tests a different way of giving vancomycin to children with sepsis to reduce the risk of kidney injury. It compares standard dosing to an approach that adjusts dose based on how the kidneys are working.
This study looks at giving vancomycin continuously in the ICU or orthopedics for the first time, to see if the dosing is done correctly. If you’re an adult receiving this treatment, the trial may help improve how safely and accurately vancomycin is managed.
This Phase 1 study tests whether the antibiotic vancomycin can be given safely to people with newly diagnosed multiple sclerosis (or related early stages). It mainly focuses on safety and side effects, and whether the approach is feasible for this group.
This research study tests a new antibiotic called vancomycin to understand how the body reacts to it and identify early warning signs. If you qualify, you'll help researchers learn more about sudden allergic-like reactions that aren't traditional allergies.
Hear when a new MRSA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.